Semax
Semax is a synthetic heptapeptide derived from an ACTH(4–7) fragment with a Pro-Gly-Pro extension.
The short version
- Why people discuss it
- Discussed for focus, memory, mental fatigue and cognitive support. Community interest does not establish benefit or a suitable treatment.
- What it is
- Semax is a synthetic heptapeptide derived from an ACTH(4–7) fragment with a Pro-Gly-Pro extension.
- Biggest caution
- Formulations, routes and regulatory contexts vary. Findings from a named medicinal preparation cannot be transferred to an unverified nasal or injectable product or treated as proof of broad cognitive enhancement.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Sources report different amounts or schedules; the reference below is a named example, not a consensus.
Intranasal
Community reference · Not clinical guidance- Amount
- 200–600 mcg total per day
- Frequency
- Once or twice daily
- Duration / phase
- 10–14 days
Community and regional-use pattern; formulations vary Reference only; this does not establish safety, effectiveness or individual suitability.
Reference source · reviewed 2026-09-12Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
200–300 mcg intranasal per administration 2–3 times/day (400–900 mcg/day), 5 days.
- Peptidepedia — saved source reviewed September 27, 2026
200–600 mcg total/day split 1–2 times, 10–30 days; higher/regional clinical contexts separate.
Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27
- Peptidepedia — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27